Patents by Inventor Jan Kuhling

Jan Kuhling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11485990
    Abstract: 1) A method for obtaining a concentrated protein-rich phase from residues of bioethanol production. 2.1) Previously, the separation of a protein-rich phase from whole stillage from bioethanol production has been achieved either by the addition of chemicals or by process steps that are complex in terms of equipment and/or energy. 2.2) Whole stillage from bioethanol production is fed to a solid-liquid separation, and the liquid phase (thin stillage) resulting from this is partially returned to the mashing process. This recirculation increases the raw protein content in the process. Part of the thin stillage is diluted and fed to a simple separation process without the addition of chemicals and temperature treatment, with a protein-rich phase being obtained. 2.3) A protein-rich phase is obtained from residues of bioethanol production.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: November 1, 2022
    Assignee: VERBIO VEREINIGTE BIOENERGIE AG
    Inventors: Julia Pohl, Jan Kühling, Michael Schlimbach, Wolfram Klein, Oliver Lüdtke, Anne Lamp
  • Patent number: 11352596
    Abstract: The invention relates to a method for producing biogas from lignocellulose-containing biomass, preferably from straw, and to a plant for carrying out said method.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: June 7, 2022
    Assignee: VERBIO VEREINIGTE BIOENERGIE AG
    Inventors: Oliver Ludtke, Michael Schlimbach, Enrico Fichter, Jens Horn, Georg Pollert, Jan Kuhling
  • Publication number: 20210002686
    Abstract: 1) A method for obtaining a concentrated protein-rich phase from residues of bioethanol production. 2.1) Previously, the separation of a protein-rich phase from whole stillage from bioethanol production has been achieved either by the addition of chemicals or by process steps that are complex in terms of equipment and/or energy. 2.2) Whole stillage from bioethanol production is fed to a solid-liquid separation, and the liquid phase (thin stillage) resulting from this is partially returned to the mashing process. This recirculation increases the raw protein content in the process. Part of the thin stillage is diluted and fed to a simple separation process without the addition of chemicals and temperature treatment, with a protein-rich phase being obtained. 2.3) A protein-rich phase is obtained from residues of bioethanol production.
    Type: Application
    Filed: June 25, 2020
    Publication date: January 7, 2021
    Inventors: Julia POHL, Jan KÜHLING, Michael SCHLIMBACH, Wolfram KLEIN, Oliver LÜDTKE, Anne LAMP
  • Patent number: 9453051
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: September 27, 2016
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbH
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • Publication number: 20160230134
    Abstract: The invention relates to a method for producing biogas from lignocellulose-containing biomass, preferably from straw, and to a plant for carrying out said method.
    Type: Application
    Filed: December 16, 2013
    Publication date: August 11, 2016
    Inventors: Oliver Ludtke, Michael Schlimbach, Enrico Fichter, Jens Horn, Georg Pollert, Jan Kuhling
  • Publication number: 20140316104
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Application
    Filed: August 29, 2012
    Publication date: October 23, 2014
    Applicants: LEAD DISCOVER CENTER GMBH, MAX-PLANCK-GUSELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • Patent number: 8618065
    Abstract: A cyclosporin derivative of general Formula (I) or a pharmaceutically compatible salt thereof, which have a pharmaceutical effectiveness, for example in the case of chronic inflammatory diseases. The cyclosporin derivatives are preferably free from a peptide section capable of passing through the membrane of a biological cell.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: December 31, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kühling, Michael Bukrinsky, Stephanie Constant
  • Publication number: 20120196749
    Abstract: A cyclosporin derivative of general Formula (I) or a pharmaceutically compatible salt thereof, which have a pharmaceutical effectiveness, for example in the case of chronic inflammatory diseases. The cyclosporin derivatives are preferably free from a peptide section capable of passing through the membrane of a biological cell.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 2, 2012
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kühling, Michael Bukrinsky, Stephanie Constant
  • Publication number: 20120058932
    Abstract: The present invention relates to an active ingredient-peptide construct for extracellular concentration, a process for the concentration of active ingredients in an extracellular space of a multicellular object, the use of the active ingredient-peptide construct according to the invention for the production of a medicinal product and a pharmaceutical composition containing the active ingredient-peptide construct according to the invention.
    Type: Application
    Filed: December 4, 2009
    Publication date: March 8, 2012
    Applicant: MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kühling, Michael Ilya Bukrinsky, Stephanie Constant